Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

FDA Clears Roche's cobas® BV/CV Assay, Enabling Fast and Highly Accurate Diagnosis of Vaginitis

Roche announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic test provides results for both Bacterial vaginosis (BV) and...

China Approves Haisco's Class 1 Innovative Drug, Ciprocopan Succinate Tablets, Providing a New Treatment Option for Patients with PNH

Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China...

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full approval in children with achondroplasia. . "This...

Industry Veteran Marie Emms Appointed President of Clinical Business at Spectrum Science

Spectrum Science, an independent, full-service, strategic platform offering integrated clinical, commercial, and communications services, announced the appointment of Marie Emms as President of its clinical trial recruitment and retention...

Avenacy Launched Norepinephrine Bitartrate Injection, USP in the U.S. Market

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Norepinephrine Bitartrate Injection, USP in the United States as a therapeutic generic equivalent for Levophed®, as...

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe...

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe...

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company announced the first patient treatment with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota. HOPE has installed Zeta TMS Navigation Systems at...

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of KYMBEE™ (deflazacort) Oral Suspension, 22.75 mg/mL indicated for the treatment of Duchenne...

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

Piramal Pharma Solutions a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. announced that it completed more than 200 customer audits and received over 70 approvals from regulatory agencies...

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen...

Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Bortezomib for Injection in the United States. The product contains the same active ingredient as VELCADE®, as approved by...

WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), announced the successful closing of an oversubscribed Series D financing...

Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

Rugiet, the performance medicine company that’s helped more than 500,000 men take control of their health, announced the expansion of its treatment areas to include longevity. Rugiet is bringing its physician-prescribed standards to an emerging...

EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

The EVERY Company ("EVERY"), a leader in highly functional egg proteins produced via precision fermentation, announced a significant manufacturing expansion with its strategic partner, Huvepharma, a global pharmaceutical company with a focus on...

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

Incyte announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to...

SEREMI de Salud Grants Registration to Chile's First Finished Product Featuring Setria® Glutathione

Kyowa Hakko, a global leader in health ingredient innovation and manufacturer of branded ingredient Setria® Glutathione, announced that a supplement featuring Setria has been approved for sale in Chile through the Secretaría Regional Ministerial...

Roquette Highlights Scalable Innovations in Drug Delivery

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions Under the theme “One Roquette for Innovations,” Roquette’s Health & Pharma...

Exilby®, a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain, Receives Its First European Marketing Authorization from VERTANICAL; Pivotal U.S. Phase 3 Trial Underway

VERTANICAL announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component. The authorization marks a major milestone for VERTANICAL and highlights...